Statement
9 Jun 2023
First-of-its-kind event brings together 10 companies that partnered to deliver vaccines and treatments in response to COVID-19
On 7 June 2023, IFPMA hosted a unique opportunity to hear from 10 companies, about the different partnership models that supported the industry’s response to COVID-19. This open event included discussion on the challenges of scaling up manufacturing to meet global demand for vaccines and treatments, with representatives from MSD – Dr Reddy’s Laboratories; Gilead...
Read more
Statement
5 Jun 2023
G20 3rd Health Working Group Meeting: Health Emergencies Prevention, Preparedness, and Response (HEPPR)
On 4 June, IFPMA delivered a statement on Priority I “Health Emergencies Prevention, Preparedness, and Response” at the G20 3rd Health Working Group Meeting in Hyderabad.
Read more
Statement
5 Jun 2023
G20 3rd Health Working Group Meeting: Strengthening cooperation in pharmaceutical sector with focus on availability and access to safe, effective, quality, and affordable medical countermeasures (MCM) – VTDs (vaccines, therapeutics, and diagnostics)
On 4 June, IFPMA delivered a statement on Priority II “Strengthening cooperation in pharmaceutical sector with focus on availability and access to safe, effective, quality, and affordable medical countermeasures (MCM) – VTDs (vaccines, therapeutics, and diagnostics)” at the G20 3rd Health Working Group Meeting in Hyderabad.
Read more
